AbbVie’s $1B Psychedelic Bet: Who’s Next in the Neuroplastogen Gold Rush? [Microdose]
Thursday, August 28, 2025 1 min read
Key Takeaway: AbbVie has acquired Gilgamesh Pharmaceuticals for nearly $1 billion, marking a significant entry of Big Pharma into the psychedelic sector. This acquisition not only makes headlines but also indicates a growing interest in neuroplastogens and their potential in mental health treatments. The move could inspire further investments in psychedelic research and development.
Price reaction · baseline $14.52 (2025-08-28T13:56:00.000Z) · hit during market hours · 3 other ENVB headline(s) in the window, move may be shared
day 0 close · peak
+4.1%
Market Sentiment Analysis
POSITIVE FACTORS
AbbVie's acquisition highlights growing interest in psychedelics.
The deal signifies Big Pharma's entry into innovative treatment areas.
Potential for new neuroplastogen therapies could reshape mental health.
Full Press Release Details
AbbVie’s quiet acquisition of Gilgamesh Pharmaceuticals, reportedly worth close to $1 billion, did more than make headlines. It signaled something far more significant: Big Pharma has officially entered the psychedelic-adjacent chat.
Full Article >>
Frequently Asked Questions
What did AbbVie acquire?
AbbVie acquired Gilgamesh Pharmaceuticals for nearly $1 billion.
What does this acquisition signify?
It signifies Big Pharma's entry into the psychedelic sector.
Why is the acquisition important?
It highlights growing interest in innovative mental health treatments.